Eligibilty

Gender



Age Group



More options for age range

Dates

Names

Showing 1 - 5 of 16 results
Page 1 of 4   

Aspire

Principal Investigator: Sif Hansdottir, MD

Department:Department or Field of Study

Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution 

Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.

Please refer to www.clinicaltrials.gov for more information identifier NCT01266265

age group:1 to 99 years trial start date:April 11, 2011
Gender Preference:none Trial End Date: January 21, 2015
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew RN 319-356-1028  pager # 2123

cynthia-larew@uiowa.edu

Keywords: Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso

TAH-t Post Markey Surveillance Study

Principal Investigator:Jennifer Goerbig-Campbell, MD

Department:Department or Field of Study

The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.

 

Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.

age group:18 to 99 years trial start date:August 1, 2006
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email: page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart failure ; Mechanical circulatory support

Ikaria

Principal Investigator: Sif Hansdottir, MD

Department:Department or Field of Study

This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).

 

Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information. 

age group:18 to 80 years trial start date:April 20, 2012
Gender Preference:none Trial End Date: September 24, 2014
Contact Info:

Pulmonary Hypertension Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

Freedom Driver Study

Principal Investigator:Jennifer Goerbig-Campbell, MD

Department:Department or Field of Study

The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to manage the Freedom Driver System safely outside the hospital.

 

Please refer to www.clinicaltrials.gov identifier NCT00733447 for more information.

age group:18 to 99 years trial start date:March 1, 2010
Gender Preference:none Trial End Date: November 28, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart Failure ; Mechanical Circulatory Support

Champion

Principal Investigator: Frances Johnson, MD

Department:Department or Field of Study

Champion: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients 

HF Pressure Measurement System

A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.

The primary hypothesis is that the TREATMENT group will have a significantly lower rate of HF-related hospitalizations than the CONTROL group. ( Time Frame: 6 months). This trial is closed to enrollment and is follow-up phase.

This trial is closed to enrollment and continues in follow up phase.

age group:18 to 99 years trial start date:September 1, 2007
Gender Preference:none Trial End Date: September 26, 2014
Contact Info:

Cardiomyopathy Treatment Program

Cynthia Larew RN  319-356-1028 pager # 2123

Keywords: cardiomyopathy ; device for treatment of heart failure ; Heart ; heart failure ; pulmonary artery pressure sensor
Page 1 of 4
« 1 2 3 4 » 
Results per page
5 | 15 | 25

Clinical Research Studies

Filter By Started within
Show trials started in last 1 month
Your Selections

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x